Back to Search

Phase I Dose Escalation and Dose Expansion Study of Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy


  • Protocol Number: 202111018
  • Principal Investigator: Ghobadi, Armin
  • Cancer Types: Gene & Cellular Immunotherapy

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

Protocol Interventions